[HTML][HTML] Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study
Objective To determine the optimal GnRH agonist dose for triggering of oocyte maturation in
oocyte donors. Design Single-center, randomized, parallel, investigator-blinded trial. Setting
IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam. Patient (s) One hundred sixty-five
oocyte donors (aged 18–35 years, body mass index [BMI]< 28 kg/m 2, antimüllerian
hormone level> 1.25 ng/mL, and antral follicle count≥ 6). Intervention (s) Ovulation trigger
with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle. Main Outcome Measure (s) …
oocyte donors. Design Single-center, randomized, parallel, investigator-blinded trial. Setting
IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam. Patient (s) One hundred sixty-five
oocyte donors (aged 18–35 years, body mass index [BMI]< 28 kg/m 2, antimüllerian
hormone level> 1.25 ng/mL, and antral follicle count≥ 6). Intervention (s) Ovulation trigger
with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle. Main Outcome Measure (s) …